$Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis$

Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis

BackgroundTirabrutinib is a potent, irreversible, and highly selective Bruton’s tyrosine kinase (BTK) inhibitor that has demonstrated significant therapeutic activity in patients with relapsed or refractory B-cell lymphoma. However, the safety and efficacy of tirabrutinib monotherapy have not been s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jingfei Wang, Hai-en Cheng, Yanhua Sun, Zhenfeng Li, Yunke Zang, Yuying Zhao, Guimao Yang, Zhijun Liu, Yaqi Sun, Yanli Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Pharmacology
Subjects:	Btk inhibitor tirabrutinib B-cell lymphomas/leukemia safety efficacy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1559056/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance
by: Xiaoqing Sun, et al.
Published: (2025-07-01)

The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
by: Nicolò Danesin, et al.
Published: (2025-07-01)

BTK inhibition in primary central nervous system lymphoma: mechanisms, clinical efficacy, and future perspectives
by: Yurou Xing, et al.
Published: (2024-12-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Ofatumumab for the management of refractory pemphigus vulgaris: A case series
by: Sera Sarsam, MBBS, BMedSc, et al.
Published: (2025-10-01)

Progression of IgM Monoclonal Gammopathy of Renal Significance (MGRS) to Symptomatic Waldenström Macroglobulinemia: A Case Report
by: Kenichi Ito, et al.
Published: (2025-07-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Response Rate After Modified Regime DHAP and Toxicity with Refractory and Relapsed Disease in Lymphoma Patients
by: Reeta Kumari, et al.
Published: (2023-10-01)

The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
by: Francesco D’Egidio, et al.
Published: (2025-07-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
by: Allison M. Bock, et al.
Published: (2025-07-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
by: Zahraa Qusairy, et al.
Published: (2025-05-01)

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
by: Yuchen Wu, et al.
Published: (2025-06-01)

A case report and literature review of a rare lymphoma with repeated fever by pain and numbness in both lower limbs
by: Xiaoqiong Duan, et al.
Published: (2025-08-01)

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
by: Ya Hwee Tan, et al.
Published: (2025-02-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)

Mantle cell lymphoma relapsing at the lymphedematous arm.
by: Giuseppina Massini, et al.
Published: (2013-02-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Shiliang Ge, et al.
Published: (2025-02-01)

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial
by: Yuqin Song, et al.
Published: (2025-05-01)

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
by: Carrie van der Weyden, et al.
Published: (2025-06-01)

Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma
by: Chao Chen, et al.
Published: (2024-12-01)

Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment
by: Laura R. Naydovich, et al.
Published: (2025-07-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis
by: Chunyu Zhang, et al.
Published: (2025-07-01)

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies
by: Oleg Demin Jr, et al.
Published: (2025-04-01)

Relapse of primary bone lymphoma: what is the therapy?
by: Patrizia Mondello, et al.
Published: (2014-08-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01)

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
by: Dennis Christoph Harrer, et al.
Published: (2025-03-01)

Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments
by: Caitlin Thomas, et al.
Published: (2024-10-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Very late relapse of Burkitt's lymphoma in an EBV-negative patient after 20 years of complete remission
by: Kmar Mrad, et al.
Published: (2024-01-01)

Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T‐Cell Lymphoma
by: Theingi M. Thway, et al.
Published: (2025-03-01)

Case Report: Neurolymphomatosis of the peripheral nerve as a presentation of relapsed pediatric high-grade B cell lymphoma
by: Evelyn Ruoyun Lu, et al.
Published: (2025-05-01)

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia
by: Priya Hays
Published: (2025-06-01)